Congress Materials
As part of our commitment to addressing unmet medical needs, Corcept investigates approved products and pipeline compounds and indications. Corcept presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. The safety and efficacy of investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.
Access Corcept congress presentations below.
Filter by:
American Society for Preventative Cardiology
2026
Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
Taub PR, Al Dhaybi O, Aroda VR, et al
Heart in Diabetes
2026
Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
DeFronzo RA, Aroda VR, Basile JN, et al
Annual Meeting of The Endocrine Society
2026
Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study
Eilerman B, Taub PR, Al Dhayabi O, et al
American Diabetes Association
2026
High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
Umpierrez G, Aroda VR, Budoff M, et al
American Diabetes Association
2026
Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
Sloan LA, Aroda VR, Busch RS, et al
American Association of Clinical Endocrinology
2026
Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study
Silverstein JM, Dobri GA, Elenkova A, et al
Annual Meeting of The Endocrine Society
2026
Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
DeFronzo RA, Aroda VR, Auchus RJ, et al
American College of Cardiology
2026
Prevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM Study
Bhatt DL
American Association of Clinical Endocrinology
2026
Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM Trial
Sloan LA, Aroda VR, Bhatt DL, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2026
Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
Olawaiye AB, Derquin F, Taylor NP, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2026
Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
Shahin MS, Snider J, Parthan A, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
Hamid O, Pacheco JM, Chandana SR, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Borazanci EH, Rasco DW, Kasi A, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2026
Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer
Gilbert L, You B, Olawaiye AB, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Real-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
Coleman RL, Mathur R, Parthan A, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Relacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression Levels
Lorusso D, Fleming GF, Colombo N, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers
Lorusso D, Monk BJ, Park JY, et al.
Society of Gynecologic Oncology (SGO) Annual Meeting
2026
Final Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer
Olawaiye AB, Quesada S, Gilbert L, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2026
Relacorilant + Nab-Paclitaxel vs Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Exposure-Response
Colombo N, Botbyl J, Kesner-Hays A, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2026
ROSELLA: A Phase 3 Study of Relacorilant + Nab-Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)
Lorusso D, Quesada S, Chan JK, et al.
American Diabetes Association
2025
A New Cause of Diabetes That Affects ~1.25M Americans: Who Woulda Thought?
DeFronzo RA
American Diabetes Association
2025
Design of the CATALYST Trial and Prevalence Results
Aroda VR
American Diabetes Association
2025
CATALYST Implications—A New Paradigm for Understanding and Treating Type 2 Diabetes
Buse JB
European Association for the Study of Diabetes
2025
Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial
RA DeFronzo, V Fonseca, VR Aroda et al
European Association for the Study of Diabetes
2025
Difficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study
Busch RS, Auchus RJ, Bailey T, et al
Association of Diabetes Care & Education Specialists
2025
Final Results of the CATALYST Trial
DeFronzo RA, Fonseca V, Aroda VR
Association of Diabetes Care & Education Specialists
2025
Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study
Auchus RJ, Bailey T, Blonde L, et al
Annual Meeting of The Endocrine Society
2025
The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Plutzky J, Auchus RJ, Basil JN, et al
Annual Meeting of The Endocrine Society
2025
Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies
Dischinger U, Al-Karadsheh A, Badiu C, et al
Annual Meeting of The Endocrine Society
2025
Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies
Hamidi O, Auchus RJ, Busch RS, et al
Pituitary Society Congress
2025
Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study
Dobri GA, Arnaldi G, Auchus RJ, et al
Heart in Diabetes
2025
The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Plutzky J, Auchus RJ, Basile JN, et al
Heart in Diabetes
2025
High Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study
DeFronzo RA, Buse J, Eilerman B, et al
American Association of Clinical Endocrinology
2025
Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
Hamrahian A, Aresta C, Badiu C, et al
American Association of Clinical Endocrinology
2025
Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study
Busch RS, Auchus RJ, Bailey T
American Association of Clinical Endocrinology
2025
A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
Hannoush ZC, Badiu C, Mangas Cruz MA, et al
American Association of Clinical Endocrinology
2025
Clinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes
Lucci CP, McCoy G
European Congress of Endocrinology
2025
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello R, Arnaldi G, Auchus RJ, et al
American Association of Clinical Endocrinology - Middle East & North Africa
2025
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
Badiu C, Auchus RJ, Bancos I, et al
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2025
Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients
Olawaiye AB, Gladieff L, Gilbert L, et al.
European Society for Medical Oncology (ESMO) Congress
2025
ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor
Lorusso R, Quesada S, Chan JK, et al.
European Society for Medical Oncology (ESMO) Congress
2025
BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers
Lorusso D, Monk BJ, Park JY, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2025
Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
Shahin MS, Mathur R, Parthan A, et al.
European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress
2025
Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints
Lorusso D, Gladieff L, Gilbert L, et al.
American Society of Clinical Oncology (ASCO) Annual Meeting
2025
ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer
Olawaiye AB, Gladieff L, Gilbert L, et al.
European Congress of Endocrinology
2024
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Badiu C, Auchus R, Bancos I, et al
Heart in Diabetes
2024
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello R, Arnaldi G, Auchus RJ, et al
Heart in Diabetes
2024
Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
DeFronzo R
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: results from CATALYST
Fonseca V, Aroda VR, Budoff M, et al.
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST
Handelsman, Y, Aroda VR, Bailey T, et al.
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome).
Auchus RJ, Gilis-Januszewska A, Badiu C, et al
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Open-label extension study evaluating the safety and efficacy of long-term use of relacorilant in patients with endogenous hypercortisolism (cushing syndrome): interim analysis results
Badiu C, Auchus RJ, Bancos I, et al
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Medical treatment of hypercortisolism with relacorilant: final results of the phase 3 grace study
Piconello R, Arnaldi G, Auchus RJ, et al
American Association of Pharmaceutical Scientists
2024
A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects
Kunta J, Donaldson K, Hynt HJ, et al.
American Association of Clinical Endocrinology - Middle East & North Africa
2024
Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Gilis-Januszewska A, Badiu C, Ranetti A-E, et al
Annual Meeting of The Endocrine Society
2024
Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)
Pivonello R, Arnaldi G, Auchus RJ, et al
American Association of Clinical Endocrinology
2024
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
Rizzo K, Ali J
Society of Gynecologic Oncology (SGO) Annual Meeting
2024
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Colombo N, Van Gorp T, Matulonis UA, et al.
The Italian Society of Endocrinology
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
Annual Meeting of The Endocrine Society
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
Annual Meeting of The Endocrine Society
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
Heart in Diabetes
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
European Congress of Endocrinology
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
European Congress of Endocrinology
2023
An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome
Badiu C, Mariash C, Kautzky-Willer A, et al
American Association of Clinical Endocrinology
2023
Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome
Donegan DM, Pivonello R, Stigliano A, et al
American Association of Clinical Endocrinology
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
International Gynecologic Cancer Society (IGCS) Annual Global Meeting
2023
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab-paclitaxel vs. Nab-paclitaxel in Platinum-Resistant Ovarian Cancer
Lorusso D, Bagameri A, Bishop E, et al.
European Society of Gynaecological Oncology (ESGO) Congress
2023
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Lorusso D, Bagameri A, Bishop E, et al.
American Association for Cancer Research (AACR) Annual Meeting
2023
Selective Glucocorticoid Receptor Modulation Reveals a New Role for CLEC10A in Patients With Solid Tumors
Colombo N, Van Gorp T, Matulonis UA, et al.